Q32 Bio Inc. (QTTB) stock
QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.63+0.34 (+4.10%)
Close on Nov 17, 2026Market cap $256.91MP/E –Yield –
Q32 Bio r&d expenses
Research and development expenses are spending on new products and technology.
Q32 Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $14.35M, down 61.4% year over year. For fiscal 2025 it was $19.16M, down 60.2% from the year before. The highest annual figure on record is $100.39M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.16M | -60.2% |
| FY2024 | Dec 31, 2024 | $48.14M | +51.7% |
| FY2023 | Dec 31, 2023 | $31.73M | -67.7% |
| FY2022 | Dec 31, 2022 | $98.35M | +5.7% |
| FY2021 | Dec 31, 2021 | $93.09M | -7.3% |
| FY2020 | Dec 31, 2020 | $100.39M | +12.3% |
| FY2019 | Dec 31, 2019 | $89.40M | +86.4% |
| FY2018 | Dec 31, 2018 | $47.95M | +124.3% |
| FY2017 | Dec 31, 2017 | $21.38M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.26M | -17.5% |
| Q1 FY2026 | Mar 31, 2026 | $3.22M | -54.8% |
| Q4 FY2025 | Dec 31, 2025 | $3.32M | -68.6% |
| Q3 FY2025 | Sep 30, 2025 | $3.56M | -75.2% |
| Q2 FY2025 | Jun 30, 2025 | $5.16M | -61.5% |
| Q1 FY2025 | Mar 31, 2025 | $7.12M | -27.6% |
| Q4 FY2024 | Dec 31, 2024 | $10.55M | +26.5% |
| Q3 FY2024 | Sep 30, 2024 | $14.35M | +92.2% |
| Q2 FY2024 | Jun 30, 2024 | $13.41M | +67.3% |
| Q1 FY2024 | Mar 31, 2024 | $9.84M | +24.4% |
| Q4 FY2023 | Dec 31, 2023 | $8.34M | -69.3% |
| Q3 FY2023 | Sep 30, 2023 | $7.46M | -71.1% |
| Q2 FY2023 | Jun 30, 2023 | $8.02M | -62.0% |
| Q1 FY2023 | Mar 31, 2023 | $7.91M | -67.4% |
| Q4 FY2022 | Dec 31, 2022 | $27.15M | +14.8% |
| Q3 FY2022 | Sep 30, 2022 | $25.85M | +7.8% |
| Q2 FY2022 | Jun 30, 2022 | $21.08M | -11.1% |
| Q1 FY2022 | Mar 31, 2022 | $24.27M | +11.6% |
| Q4 FY2021 | Dec 31, 2021 | $23.65M | +1.9% |
| Q3 FY2021 | Sep 30, 2021 | $23.99M | +17.5% |
| Q2 FY2021 | Jun 30, 2021 | $23.70M | -13.7% |
| Q1 FY2021 | Mar 31, 2021 | $21.76M | -25.8% |
| Q4 FY2020 | Dec 31, 2020 | $23.20M | +14.0% |
| Q3 FY2020 | Sep 30, 2020 | $20.42M | -20.5% |
| Q2 FY2020 | Jun 30, 2020 | $27.47M | +20.3% |
| Q1 FY2020 | Mar 31, 2020 | $29.31M | +42.7% |
| Q4 FY2019 | Dec 31, 2019 | $20.34M | +24.9% |
| Q3 FY2019 | Sep 30, 2019 | $25.69M | +91.8% |
| Q2 FY2019 | Jun 30, 2019 | $22.83M | +121.8% |
| Q1 FY2019 | Mar 31, 2019 | $20.54M | +156.8% |
| Q4 FY2018 | Dec 31, 2018 | $16.28M | +70.0% |
| Q3 FY2018 | Sep 30, 2018 | $13.39M | +170.8% |
| Q2 FY2018 | Jun 30, 2018 | $10.29M | +153.7% |
| Q1 FY2018 | Mar 31, 2018 | $8.00M | +185.7% |
| Q4 FY2017 | Dec 31, 2017 | $9.58M | – |
| Q3 FY2017 | Sep 30, 2017 | $4.95M | – |
| Q2 FY2017 | Jun 30, 2017 | $4.06M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.80M | – |
See a number that looks wrong?